Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis

Biomaterials ◽  
2020 ◽  
Vol 258 ◽  
pp. 120296
Author(s):  
Ting Gong ◽  
Tiantian Tan ◽  
Pei Zhang ◽  
Haohuan Li ◽  
Caifeng Deng ◽  
...  
Luminescence ◽  
2014 ◽  
Vol 30 (5) ◽  
pp. 583-591 ◽  
Author(s):  
Jitendra Wagh ◽  
Kuldeep J. Patel ◽  
Parth Soni ◽  
Krutika Desai ◽  
Pratik Upadhyay ◽  
...  

2021 ◽  
Vol 18 ◽  
Author(s):  
Monica Joshi ◽  
Khushwant S. Yadav ◽  
Bala Prabhakar

Background: Rifampicin is one of the first line drugs used for tuberculosis therapy. The therapy lasts for a long time. Thus, there is a need to develop sustained release formulation of rifampicin for intravenous application. Aim: This study is focused on preparing rifampicin loaded bovine serum albumin nanoparticles (RIF BSA NPs) suitable for intravenous application using systematic quality by design (QbD) approach. Objectives: The main objective of this study is optimizing particle size and entrapment efficiency of rifampicin loaded bovine serum albumin nanoparticles (RIF BSA NPs) and making it suitable for intravenous application using QbD approach. Methods: Quality target product profile was defined along with critical quality attributes (CQAs) for the formulation. 32 factorial design was used for achieving the predetermined values of CQAs, i.e., mean particle size <200 nm and percent entrapment efficiency>50%. Incubation time of drug with colloidal albumin solution and ratio of rifampicin: albumin, were selected as independent variables. Check point analysis was performed to confirm the suitability of regression model for optimization. Results: : The optimized RIF BSA NPs were characterized by FTIR, DSC, 1H NMR techniques. The NPs observed by transmission electron microscopy were spherical in shape. The rifampicin release could be sustained for 72 hours from BSA NPs matrix. RIF BSA NPs dispersion was stable at 5 ± 3°C for 72 hours. Non-toxicity of nanoparticles to RAW 264.7 cell line was proved by MTT assay. Conclusion: Development of RIF BSA NPs with desired quality attributes was possible by implementing QbD approach. The optimized formulation suitable for intravenous application can potentially improve the therapeutic benefits of rifampicin.


Drug Delivery ◽  
2019 ◽  
Vol 26 (1) ◽  
pp. 89-97 ◽  
Author(s):  
Haipeng Wang ◽  
Shuilin Sun ◽  
Yu Zhang ◽  
Jiayi Wang ◽  
Shouhua Zhang ◽  
...  

2019 ◽  
Vol 54 (11) ◽  
pp. 8613-8626 ◽  
Author(s):  
Danfeng Wang ◽  
Na Liang ◽  
Yoshiaki Kawashima ◽  
Fude Cui ◽  
Pengfei Yan ◽  
...  

2015 ◽  
Vol 9 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Ali Jebali ◽  
Seyedhossein Hekmatimoghaddam ◽  
Bahram Kazemi ◽  
Jesus Martinez De La Fuente

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Kyoko Honne ◽  
Takao Nagashima ◽  
Masahiro Iwamoto ◽  
Toyomi Kamesaki ◽  
Seiji Minota

A 57-year-old man with rheumatoid arthritis developed severe anemia during treatment with adalimumab plus methotrexate. Cold agglutinin disease was diagnosed because haptoglobin was undetectable, cold agglutinin was positive (1 : 2048), and the direct Coombs test was positive (only to complement). Although the cold agglutinin titer was normalized (1 : 64) after treatment with prednisolone (0.7 mg/kg/day for two weeks), the patient’s hemoglobin did not increase above 8 g/dL. When cold agglutinins were reexamined using red blood cells suspended in bovine serum albumin, the titer was still positive at 1 : 1024. Furthermore, the cold agglutinin had a wide thermal amplitude, since the titer was 1 : 16 at 30°C and 1 : 1 at 37°C. This suggested that the cold agglutinin would show pathogenicity even at body temperature. After the dose of prednisolone was increased to 1 mg/kg/day, the patient’s hemoglobin rapidly returned to the normal range. The thermal amplitude test using red blood cells suspended in bovine serum albumin is more sensitive than the standard test for detecting pathogenic cold agglutinins.


Sign in / Sign up

Export Citation Format

Share Document